Networking antibodies

Even before Jan van de Winkel was promoted to president and CEO of Genmab A/S in June, the company had realized it was living beyond its means and started paring back. He has accelerated the process, putting forward what he believes is a more realistic strategy: the company will delay its transition into a commercial organization and, in the near to mid-term, hopes to turn its antibody R&D engine into a profit center.

With a valuation one-fourth what it was two and a half years ago, and half the cash it had then, cash preservation is now a key focus...